Key result
Tirofiban benefits patients with unstable angina, non-Q-wave MI, and those undergoing PCI.
Tirofiban is a GP IIb/IIIa receptor antagonist that shows beneficial effects in acute coronary syndromes and PCI, and is particularly cost-saving when reserved for patients with elevated troponin levels.
May support selective tirofiban use in troponin-positive ACS/PCI; leaves open its role versus modern regimens.
Tirofiban: a novel GP IIb/IIIa receptor antagonist. Tirofiban is a non-peptide GP IIb/IIIa receptor antagonist, which blocks the final common pathway of platelet activation specifically and reversibly. Recent clinical trials suggest beneficial effects of tirofiban in patients with unstable angina pectoris / non-Q-wave myocardial infarction and in patients undergoing percutaneous coronary interventions. Bleeding complications and thrombocytopenia are rare adverse effects associated with tirofiban; the severity of bleeding complications is related to the dose of concomitant heparin administration. Tirofiban is particularly cost-saving, if treatment is reserved for patients with elevated troponin levels during acute coronary syndromes.
No takes yet. Share an insight, caveat, or question.
Meyer et al. (2000) conducted a review in Unstable angina pectoris, non-Q-wave myocardial infarction, and percutaneous coronary interventions. Tirofiban was evaluated. Tirofiban shows beneficial effects in patients with unstable angina, non-Q-wave myocardial infarction, and those undergoing percutaneous coronary interventions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: